An act relating to toxic heavy metals in baby food products
What changed between versions
The effective date for the main baby food testing and labeling provisions was changed from July 1, 2026 to January 1, 2027, giving manufacturers an additional six months to comply.
The trigger for Vermont's infant formula provisions to take effect was changed from when California or two other states have 'enacted legislation' with comparable requirements to when 'a law has taken effect' in those states, meaning the laws must actually be in force rather than merely passed.
A new federal preemption clause was added stating that nothing in the section shall be construed to conflict with federal law or regulation, reducing the risk of a legal challenge based on federal-state conflict.
Multiple sections now explicitly limit applicability to products 'sold or distributed in the State,' clarifying that the law targets products entering Vermont's market rather than all products a manufacturer makes.
The grounds for suspending infant formula requirements were expanded to include 'evidence of a declining supply' in addition to insufficient supply, and the Attorney General must now consult with the Commissioner of Health before suspending application.
The authority to request test results and receive consumer reports was shifted from the Commissioner of Health to the Office of the Attorney General. The defined term 'Commissioner' was removed entirely.
Consumer reporting of suspected violations was changed from mandatory ('shall report') to voluntary ('may report'), removing any obligation on consumers to report problems.
Language was added stating that manufacturers must make test results publicly available 'without requiring the provision of a universal product code or proof of purchase,' ensuring consumers can access information without barriers.
Section (b) was changed from prohibiting products exceeding 'limits established by the U.S. FDA' to those exceeding 'regulatory limits established by the U.S. FDA,' narrowing the scope to formal regulatory limits rather than any FDA guidance or action level.